Drug intelligence / Profile preview

HJ787

Development stage: Unknown
Lead developer: 成都华健未来科技
Modality: Small Molecules
Administration: Topical

Overview

HJ787 is a novel, topical small molecule androgen receptor (AR) antagonist developed by Chengdu Huajian Future Technology for the treatment of acne vulgaris. The drug is designed to specifically target and inhibit the androgen receptor within the skin's sebaceous glands, thereby reducing sebum production, which is a key driver in the pathogenesis of acne. By utilizing a topical formulation, HJ787 aims to provide localized therapeutic effects while minimizing systemic exposure and the potential for systemic anti-androgenic side effects. It is currently being evaluated in clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with moderate-to-severe acne.

Other names: HJ787 OintmentHJ-787 OintmentHJ 787 Ointment

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on HJ787.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HJ787.

Explore the full profile